What is Naltrexone?

The short answer

In the US, you need a prescription to get Naltrexone.

5 sources
Status as of October 7, 2026
How we source
Ellum doesn't sell peptides.

By Ellum EditorialUpdated October 7, 2026AI use

Get updates on Naltrexone

State

We'll store your email, your state, the page you're on and the peptides selected below (pre-selected from this page; untick any). Together these can reveal health interests. We use them only for what you tick below and to count sign-ups by state and peptide, without emails, to plan where the clinic opens and for reports that show only totals. Our hosting, database and email providers handle them for us. We pass them to a doctor or clinic only if you tick that box, and we don't sell them. Withdraw anytime with the unsubscribe link or at hello@ellumclinic.com. Consumer Health Data Privacy Policy

Ellum's sign-ups are for adults 18 and over.

Peptides: Naltrexone (1 selected) · edit

Peptides you're interested inNaltrexone

Add another molecule

What we may email you about

Notify me when an Ellum Clinic doctor can see me in my state

Send me updates on Naltrexone

More options (optional): research, doctor contact, paid offers

Contact me about taking part in research (optional)

Send my email, state and peptides to Ellum Clinic or a doctor licensed in my state, so they can contact me about care (optional)

Email me paid offers from clinics and health companies, picked for my peptides and state. Ellum sends them; the companies don't get my details (optional)

What it is

Type: Opioid antagonist (not a peptide)
Also known as: naltrexone tablets, vivitrol

Regulatory status

FDA-approved (Rx) How we label status

As of October 7, 2026, Naltrexone is an FDA-approved prescription drug for alcohol dependence; blocking the effects of opioids; preventing relapse to opioid dependence after detox (Vivitrol); chronic weight management with bupropion (Contrave).

See Naltrexone in the Index →

Federal (FDA): Approved Rx (ReVia NDA018932 1984, disc.; generic 50 mg tablets; Vivitrol NDA021897 2006, extended-release injection; with bupropion in Contrave NDA200063 2014)
503A compounding: Approved-drug component (not in any 503A category) (as of May 14, 2026)
WADA 2026: Not named

References

Sources as of October 7, 2026